Phenotypic screening the host antimicrobial responses towards the eradication of Mycobacterium tubercuosis

Información del proyecto

PHANTOM

Identificador del acuerdo de subvención: 795224

DOI

10.3030/795224

Proyecto cerrado

Fecha de la firma de la CE 23 Marzo 2018

Fecha de inicio 1 Octubre 2018

Fecha de finalización 30 Septiembre 2020

Financiado con arreglo a

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coste total

€ 170 121,60

Aportación de la UE

€ 170 121,60

Coordinado por

FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA
Spain

Periodic Reporting for period 1 - PHANTOM (Phenotypic screening the host antimicrobial responses towards the eradication of Mycobacterium tubercuosis)

Período documentado: 2018-10-01 hasta 2020-09-30

Resumen del contexto y de los objetivos generales del proyecto

The co-evolution between hosts and their parasites is one of the most fascinating – yet still almost unexplored - examples of evolutionary adaptation. There is a paucity of information, however, on how the human immune system co-adapts to the parasites phenotypic plasticity, and how it dynamically rearranges its molecular phenotypes aiming to counteract the pathogenic threats. Hence, many therapies for the treatment of intracellular bacteria-related infections are currently obsolete, especially because of the rise in drug resistance. In this framework, the goal of my proposal was to decipher the unexplored phenotypic ‘bar-codes’ of host-pathogen interaction, to reversely engineer a drug delivery platform targeting infected cells only, and to eradicate intracellular parasites. The final aim will be the eradication of the severe intracellular pathogens Mycobacterium tuberculosis (Mtb), as is the major cause of mortality related to bacterial infection worldwide.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

I focused first on the artificial recreation of the hallmark of every human tuberculosis infection, which is a necrotic granuloma. I was able to reconstruct not only its phenotypical features but also the macrophages sub-population characterizing it. I then infected these organoids and screened what kind of receptors macrophages express upon infection. This can be considered as a sort of ‘flag’ of infection, which makes it easier to produce drug directed towards infected cells only. I used this information to create nanoparticles able to recognize and target only those macrophages having the ‘flag’ of infection.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

To date, the only way we approach infectious diseases is the use of antibiotics which are administered through all the body. Inevitably, the big problem is that these drugs diffuse passively and several times they can interact with random and not-desired target (off-target), which are the reasons behind the rise in side effect and drug resistance. This project demonstrates we can do a big step ahead in the development of highly precise drugs that target only infected cells and that are much more effective in the delivery process. This means we can treat patients with much less drug for a shorter period of time, and boost thus the eradication of drug resistance phenomenon.

phantom-acs-nano-cover.jpg